Articles published by Turn Therapeutics, Inc.

Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer

September 09, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Tickers TTRX

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

July 07, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Tickers TTRX

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

July 06, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Tickers TTRX

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group

March 24, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Tickers TTRX

Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs

February 17, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Tickers TTRX

Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From Turn Therapeutics, Inc.

Via Business Wire

Tickers TTRX

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.